| Name | Title | Contact Details |
|---|---|---|
Vinay Bhupathy |
General Counsel | Profile |
Medivation Inc., which is now a part of Pfizer, Inc. is focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation`s goal is to transform the treatment of these diseases and offer hope to critically ill patients and their families. With the approval of Xtandi (enzalutamide) capsules in late August 2012 and the product launch immediately following, Medivation is continuing to build and develop a world-class workforce to take the company to the next strategic level. Medivation was founded in 2004 by a group of experienced professionals with a long track record of working together successfully as a team in the pharmaceutical and biotechnology industries. They founded Medivation to leverage that expertise to bridge the medical product development gap between early-stage development and product launch. Medivation currently has 500+ employees located in beautiful downtown San Francisco, CA.
Ben Venue-Bedford Laboratories, Inc. is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
AmerisourceBergen Drug Corporation is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Catamaran Bio is developing novel, off-the-shelf CAR-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWINDTM Platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures and Astellas Venture Management.
Relay Therapeutics is building the world`s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016. To date, Relay Therapeutics has raised $120M in financing from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), an affiliate of D.E. Shaw Research, Casdin Capital, EcoR1 Capital, Section 32 and Alexandria Venture Investments. Our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you`re creative, collaborative and passionate about making a difference in the lives of patients, join us!